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Abstract

Introduction Across the world, health systems are
adopting approaches to manage rising healthcare costs.
One common strategy is a medication copayments scheme
where consumers make a contribution (copayment)
towards the cost of their dispensed medicines, with
remaining costs subsidised by the health insurance
service, which in Australia is the Federal Government. In
Australia, copayments have tended to increase in
proportion to inflation, but in January 2005, the copayment
increased substantially more than inflation. Results from
aggregated dispensing data showed that this increase led
to a significant decrease in the use of several medicines.
The aim of this study is to determine the demographic
and clinical characteristics of individuals ceasing or
reducing statin medication use following the January 2005
Pharmaceutical Benefit Scheme (PBS) copayment increase
and the effects on their health outcomes.
Methods and analysis This whole-of-population
study comprises a series of retrospective, observational
investigations using linked administrative health data on
a cohort of West Australians (WA) who had at least one
statin dispensed between 1 May 2002 and 30 June 2010.
Individual-level data on the use of pharmaceuticals, general
practitioner (GP) visits, hospitalisations and death are
used. This study will identify patients who were stable users
of statin medication in 2004 with follow-up commencing
from 2005 onwards. Subgroups determined by change in
adherence levels of statin medication from 2004 to 2005 will
be classified as continuation, reduction or cessation of statin
therapy and explored for differences in health outcomes and
health service utilisation after the 2005 copayment change.
Ethics and dissemination Ethics approvals have been
obtained from the Western Australian Department of Health
(#2007/33), University of Western Australia (RA/4/1/1775)
and University of Notre Dame (0 14 167F). Outputs from
the findings will be published in peer reviewed journals
designed for a policy audience and presented at state,
national and international conferences.

Introduction
The global trend of both public and private
health insurance services is moving towards

Strengths and limitations of this study
►► Using the whole-of-population, cross-jurisdictional,

linked administrative data will allow exploration of
factors that might affect a person’s decision to cease
or reduce their medication due to cost, providing
the most detailed information to date regarding the
effects from the January 2005 copayment increase.
►► A major strength of this study is the use of timeseries drug data linked to primary care visits, death
and hospital admissions. Administrative data are
objective and provide complete records.
►► Limitations include that the Pharmaceutical Benefit
Scheme database has month and year rather than
full date of supply for each entry, and does not have
dosage information. Additionally, consumer’s direct
account of decision making associated with change
in usage is unknown.

adapting effective ways to manage the rising
healthcare costs. Within Australia, the
number of prescriptions and cost of medicines have been increasing over the last two
decades,1 reflected by similar increases in
other western nations as populations age and
disease patterns change. Patient copayments
are one of many policies that the Australian
Government has adopted to manage this.1
The Australian Pharmaceutical Benefit
Scheme (PBS) provides subsidised medicines
for Australian residents and is subsidised by
the Australian Government Department of
Health.2 The Repatriation Pharmaceutical
Benefit Scheme (RPBS) is subsidised by
the Australian Government Department of
Veterans’ Affairs (DVA) and covers a broader
range of medications to eligible veterans.2
In 2010, an estimated 271 million
prescriptions were dispensed by community
pharmacies, with 75% of the prescriptions
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subsidised by the PBS and the RPBS at a cost to the
Australian Government of $16.4 billion.1 By comparison, in 2014/15, there were 302 million prescriptions
dispensed of which 223 million were PBS/RPBS-subsided
medications,3 representing an 11% growth in prescription numbers over the 5 years.
Under the PBS and RPBS, consumers pay a part cost
towards their medicines dependent on their financial
status: general or concessional. Once a family reaches
a certain expenditure threshold from their cumulative
PBS copayments in a calendar year, they are issued a
Safety-Net card providing additional financial support
through further subsidies on medication.4
Copayments increase on the 1st of January each year
generally in line with the Consumer Price Index.2 The
largest individual increase in copayments in recent times
was in January 2005, when a 21% increase in consumer
co-payments occurred for PBS medications for both
general patients (from $23.70 in 2004 to $28.60 in 2005
per item dispensed) and concessional patients ($3.80–
$4.60 per item dispensed).4
Sharp increases in the copayment threshold are of
potential concern from a patient and population health
perspective. National and international evidence suggest
that rising costs of medication can result in patients
ceasing or reducing their medication often without clinical consultation.5–7
Previous research using aggregated data has demonstrated that following the PBS copayment increase
in January 2005, there was a significant decrease in
dispensing of between 3% and 11% for 12 out of the
17 medicine classes examined.5 The largest reductions
observed during this period were seen for concessional
patients rather than general patients. Essential medicines
used to manage serious but asymptomatic conditions,
including lipid-lowering therapy, were among the most
affected in terms of reduced dispensing after the copayment increase with dispensing decreasing by 5%.8 In a
separate study based on patient self-report, the same
authors found that the population groups most likely to
reduce their medications due to cost were young adults,
low-income earners, the chronically ill, those with high
out-of-pocket costs, Aboriginal and Torres Strait Islanders
and patients who did not feel involved in decisions about
their treatment.9 Many of these groups are also generally known to have poorer health outcomes.10 Therefore,
additional costs may have a more pronounced effect on
the health outcomes for these groups. A 2013 study, in
Australia, demonstrated that the likelihood of facing
substantial financial burden becomes significantly higher
for each additional chronic disease experienced due
to extra out-of-pocket healthcare costs.11 Additionally,
self-report surveys provide estimates that 12% of Australians did not get medication dispensed at the pharmacy
or skipped doses of prescribed medication due to cost.12
The relationship between financial stress and failure to
purchase necessary medical services or medicines was
also emphasised in a study where it demonstrated that a

quarter of those under financial stress forgo medical care
and refilling their prescriptions.13
International research has shown that ceasing a medication due to cost can have implications on health outcomes
and increase health service utilisation.14 15 Additionally,
it has been demonstrated that improved adherence to
essential medicines can lead to savings in other health
expenditure.16 17
What is currently unknown in Australia is the flow-on
effect from increased copayments to subsequent health
services utilisation including frequency of general practitioner (GP) consultations and adverse health outcomes
including unplanned hospitalisation or death. For
example, it is unknown for any individuals who discontinued or reduced their medication if they were under
more or less clinical supervision before, during and after
this time. While copayments may reduce some of the cost
burden to the Government, this may have unintended
negative effects if higher costs are incurred elsewhere
in the healthcare system through the increased need for
secondary healthcare and premature morbidity.7 15 18
The main aim of this study will explore the effect of an
increase in patient contributions (consumer copayments)
for PBS-subsidised medicines in 2005 on health service
utilisation and health outcomes, among people using
prescribed statins as lipid-lowering therapy. This group
was selected because research has shown that statin users
were affected by increasing costs.5 8 19 Statins are used
for asymptomatic conditions, but the consequences of
discontinuing statins are potentially serious. Use of statins
for primary prevention reduces all-cause mortality and
cardiovascular (CV) events among people with low-CV
or high-CV risk,20 while use as secondary prevention
significantly reduces the risk of a further CV event.20 21
Due to the known positive benefits of statin medication,
the prescribing rate is high across Australia.22 However, a
change in copayments that leads to reduced use may result
in poorer outcomes or poorer compliance. Poor compliance has been attributed to many factors including the
dosing frequency, financial burden, lack of concessional
card, low income, less CV morbidity at commencement
of therapy, frequency of GP visits, depression, dementia
and age.23–27
The aim of this study will be achieved through the
following five objectives:
Objective 1: To determine whether consumers who
ceased or reduced statin medication use have different
demographic and clinical characteristics across 2000
to 2004 compared with those who continued to take
their medication after the January 2005 PBS copayment
increase.
Objective 2: To compare hospitalisation rates from
2006 to 2010 between consumers who ceased, reduced or
continued statin medication after the January 2005 PBS
copayment increase.
Objective 3: To measure the risk of death from 2006
to 2010 (all-cause or coronary heart disease) between
consumers who ceased, reduced or continued statin
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medication after the January 2005 PBS copayment
increase.
Objective 4: To investigate whether regularity and
frequency of health service use in the 12 months prior to
January 2005 PBS copayment increase affected the rate
at which consumers ceased, reduced or continued statin
medication.
Objective 5: To examine whether consumers who
ceased or reduced statin medication after the January
2005 copayment increase concurrently ceased or reduced
other medications in 2005 compared with 2004.
Methods
Study design and population
This retrospective observational study uses whole-of-population administrative data in Western Australia (WA).
The initial data extract for the total statin cohort was
identified from PBS data and included individuals who
had at least one statin medication dispensed in the period
between 1 May 2002 and 30 June 2010. Statins were identified by any of their primary anatomical therapeutic
chemical (ATC) codes (C10AA01, C10AA03, C10AA04,
C10AA05, C10AA06 and C10AA07).
The WA population was chosen due to the long-standing
data linkage system in this State. Comparisons of national
census data and health statistics have indicated that WA
was the most representative population of Australia’s
eight jurisdictions.28 Hence, findings from this study are
expected to be applicable to the Australian population.
Data sources
The study will use linked datasets extracted from multiple
State and Commonwealth population-based administrative data collections (figure 1). PBS and Medicare
Benefits Scheme (MBS) data were obtained from the
Australian Government Department of Human Services.

Figure 1

The other two datasets were extracted from the WA
Hospital Morbidity Data Collection (HMDC) and WA
Mortality Register. The HMDC and mortality register are
two core datasets of the WA Data Linkage System.29 The
study cohort was identified from the PBS data, and PBS
records were linked to matching MBS, HMDC and death
records.
PBS data contain records for each pharmaceutical
product that is subsidised by the Australian Government
and supplied by PBS-approved pharmacies. The data
include item name and strength, PBS item code, ATC
classification code, month and year of supply, quantity
dispensed, repeat number, beneficiary status (concessional or general), patient gender, age and Accessibility
Remoteness Index of Australia (ARIA+) code30 based on
patient postcode and an index of relative socioeconomic
disadvantage (Socio-Economic Indexes for Areas) based
on patient postcode.31
The MBS data contain information related to health
services used outside the hospital setting including GP
consultation, diagnostic services and laboratory tests.
These services are subsidised by the Australian Government and the data include information on service type,
date of service and patient age.
The HMDC is a statutory data collection that is compiled
from all inpatient admissions supplied by all hospitals
(public and private) in WA. The data supplied provide
information on admitted patient care including demographics, length of stay, diagnoses (principal discharge
diagnosis and up to 20 secondary discharge diagnoses),
procedures (primary and up to 10 secondary) and
external cause codes for injury and poisoning. For the
period of this study, the diagnoses and procedures were
recorded using the International Statistical Classification
of Diseases and related health problems Tenth revision,
Australian Modification (ICD-10-AM).32

Study dataset sources from State (Western Australia) and Australian Government administrative health data.
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Table 1 Statin medications above and below the general copayment
Description

Name and strength

Statin medications above the general beneficiary copayment Atorvastatin 10/20/40/80 mg; fluvastatin 40 mg; pravastatin
10/20/40/80 mg; simvastatin 10/40/80 mg
Statin medications below the general beneficiary copayment Fluvastatin 20 mg; simvastatin 5 mg
as of 1 December 2005
Note: All statin medications were above the concessional copayment.

The WA Mortality Register includes records for each
registered death in WA and includes information on date
of death, cause of death (primary and contributing) and
patient's gender, postcode and age at death.
Limitations of PBS and MBS data
There are some limitations with the PBS and MBS data.
Specifically, PBS data prior to 1 July 2012 were not
collected for medications below the patient copayment
or dispensed privately. In relation to statin medications, there were two item codes (of 14 items) below the
general copayment threshold during the study period
(see table 1), but none below the concessional copayment
threshold. For this reason, results will be stratified to look
at concessional and general beneficiaries separately.
PBS data do not include the prescribed dose nor the
frequency, so the dose per day is unknown. Additionally,
some patients may have ceased taking a statin medication
because they switched to another lipid-lowering medication that is not a statin medication, these patients will
be excluded. This represented, in 2004, 3% of overall
lipid-lowering use dispensing.33
While MBS data capture all health services provided
outside the public hospital setting, they do exclude
services provided to public inpatients, DVA card holders,
patients treated at Aboriginal Medical Services and diagnostic information including reason for consultation and
pathology test results.34
Study cohort
The study cohort was identified from the total statin
cohort and included patients who were stable statin users
as of December 2004. As month not day of supply was
provided, a stable user was defined as a patient who had
at least 60 days’ supply in the last 3 months of 2004 (the
average prescription refill rate for statin medication is
every 35 days) (see box 1). Patient’s aged <18 years in
2004, died in 2004 or 2005 or who had an excessive supply
of statin medication during 2004 were excluded from the
study (see box 1). Excessive supply was defined as >1.5
years of supply of statin medications during 2004 (<0.5%
of total cohort) (see box 1). Sensitivity subanalysis will
be conducted on the definition. All stable users will be
further classified as a ‘new user’ if they have no dispensing
of a statin medication in 2002 or 2003 otherwise they be
classified as an ‘existing user’. In 2004 in WA, there were
2 213 959 dispensing records for a statin medication for
262 330 patients.
4

After defining the study cohort, adherence will be
calculated for the years 2004 and 2005 using the portion
of days covered (PDC) method calculated from the start
of 2004 or when they commence a statin medication in
2004.23 The level of adherence will be compared between
2004 and 2005 to evaluate change in usage. Three groups
will be identified within the study cohort to identify
changes in the dispensing of statins (table 2): (i) those
‘continuing’ statin medications (<20% change) (ii) those
who ‘reduce’ the amount of statin medication (greater
than 20% change); and (iii) those who ‘cease’ taking
statin medications. Sensitivity Analysis will be conducted
around changes in reduction of PDC levels. Cessation of
statin medications in 2005 will be defined as no dispensing
of a statin medication for a period of 6 months in 2005.
This takes into consideration the stockpiling phenomenon that happens at the end of each year, in this case
2004. This phenomenon occurs when consumers reach
the safety net spending threshold for PBS medicines and
are entitled to free medicines or a reduced copayment
for the remainder of the calendar year.35 This can result
in consumers filling additional prescriptions towards the
end of the year before they return to their usual copayment the following January. Hence, excess medication will
be carried forward to ensure PDC is not under estimated.
Time of discontinuation will be calculated as the time of
last dispensing plus 3 months.
The study period will vary for each objective ranging
from 1 January 2000 to 31 December 2010.

Box 1 Entry criteria into the study defined as stable statin
user as of December 2004 inclusion and exclusion criteria
Inclusion criteria ‘stable user’
►► ≥1 supply of a statin medication between 1 January and 31

December 2004; and 60 days’ supply in the last 3 months of 2004
or >150 days of supply in the last 6 months of 2004.

Exclusion criteria
►► Age <18 years in 2004.
►► Died in 2004 or 2005.
►► >550 days’ supply of a statin medication in 2004.

New user
►► If no dispensing of a statin medication in 2002 or 2003.
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Table 2 Groups of statin users to be identified in the study cohort
Type of statin user

Definition

Continuing
Reduced
Ceased

Maintained the same or greater level of adherence from 2004 to 2005 (≤20% change)
Level of adherence decreases from 2004 to 2005 (>20% change)
No dispensing of a statin medication for a period of 6 months in 2005

Other explanatory factors to consider
Patient age, gender, ‘new’ statin user (initiated statin
therapy in 2004), PBS beneficiary status (general or
concessional) and other PBS-subsidised prescription
medication use will be ascertained from the PBS dataset.
This will include a number of additional medications to
measure the extent of comorbidity, however it is more
related to the study as exploring the impact of cost. Social
disadvantage ascertained from the PBS data will be classified by applying an area-based measure of disadvantage
(the Index of Relative Socioeconomic Disadvantage31)
to each record based on the residential postcode. This
will be divided into quintiles, with one representing most
disadvantaged and five representing least disadvantaged.
Level of remoteness (ARIA+) will be identified from the
residential postcode in the PBS data and categorised
as major cities, inner regional, outer regional, remote,
very remote and unknown.30 To determine primary or
secondary prevention status, previous myocardial infarction (MI, ICD-10-AM I21), or stroke (ICD-10-AM I60-I64)
with look-back to 2000 will be ascertained from any of the
diagnosis fields in the HMDC data.32
Change in PDC covered across 2004 and 2005 will be
considered both as a categorical and a continuous variable at time zero for the follow-up of outcomes. In order
to address immortal time bias and to reduce the likelihood of over estimating hospitalisation and death, the
follow-up period will commence from 2006 onwards. In
addition, hospitalisation and death in the months after
2005 arguably would not be due to statin discontinuation.
Statistical analysis
Objective 1: For this objective, the three outcome variables will refer to type of statin user dichotomized as
continuing, reduced and ceased as defined in table 2. The
study period is defined as 2000 to 2005. Crude differences
in characteristics between the three groups of the study
cohort will be initially compared using t-tests and χ2 tests.
Univariate and multivariate logistic regression models will
then be developed and run to determine the association
between patient clinical and demographic characteristics at baseline and statin use based on PBS-dispensed
records. Unadjusted and adjusted ORs and 95% CIs will
be calculated for each individual characteristic and for
the three outcome variables. Bonferroni correction will
be applied to account for multiple testing. Additionally,
stratification by beneficiary status will be conducted
Objective 2: The primary analysis here will report the
hazard ratios for hospitalisation for any causes or for MI
or stroke from 2006 to 2010. The study period is defined

as 2000 to 2010. Cause-specific diagnoses will be identified
from the principal discharge diagnosis field in the HDMC
dataset by using ICD codes (MI: I21, Stroke: I60–I64).32
Multivariate Cox proportional hazards regression modelling will be used to determine the difference in hazard
rates between the three statin user groups: continuing,
reduced and ceased. Any individual’s hospitalisation due to
a cardiac event prior to 2005 will be treated as a fixed effect
in the Cox model. Subsequent analysis will be performed
to assess the effects of other predictors due to differences
in the baseline demographics and clinical characteristics of
the two cohorts that are also associated with hospitalisation
using multivariate Cox regression modelling.
Objective 3: The primary analysis for this objective will
report on the risk of death for the two groups by all cause
of death and coronary heart disease. The study period
is defined as 2006 to 2010. Cause of death will be determined by ICD codes from the coded cause of death field in
mortality data (coronary heart disease: I20–I25).32 Differences in the risk of death between patients who continue
statins and those who reduce or cease their statins will
be compared using the log-rank test (unadjusted KaplanMeier risk) and by Cox proportional hazards regression
to calculate the HR.
Objective 4: The primary analysis will report on the
frequency and periodicity of GP visits and specialist visits
for the study cohort from MBS data. The study period
is 2004. Commencing from the date of entry into the
study cohort, we will measure the annual intensity (ie,
incidence rate) of service contact for each person to
determine if more or less clinical supervision affects an
individual’s decision to continue, reduce or cease medication. Previous published work has developed and trialled
a periodicity score and to estimate regularity of service
provision and these methods will be used in our study.36–39
Subsequent analysis will be performed to assess the effects
of differences in the baseline demographic and clinical
characteristics of the cohorts using multivariate regression modelling.
Objective 5: The primary analysis will describe the type
and frequency of additional medications that were ceased
or reduced after January 2005 for those who had reduced
or ceased their statin therapy, and identify medications
other than statins more likely to be ceased or reduced.
The study period is defined as 2004 to 2005. Generalised
estimating equation modelling will be performed to
identify subgroups at greater risk of ceasing other medication(s) by their demographic and clinical baseline
characteristics.
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Ethics and dissemination
Ethics approval was obtained from the human research
ethics committees (HREC) of The Western Australian
Department of Health (#2007/33), The University of
Western Australia (RA/4/1/1775) and The University of Notre Dame (0 14 167F). A wavier of consent was
approved by the HREC committees to provided linked
de-identified data to the researchers in order to conduct
this study.
The large amount of data available will result in several
publications and will be presented at state, national and
international conferences. The results from the study
will ensure that all stakeholder groups including Government, policy makers, consumers, the pharmaceutical
industry, pharmacy and medical groups will be informed
about the outcome to guide future policy.
Discussion
This research will provide the first individual-level
evidence of the effect of the PBS consumer copayments
on health outcomes and the broader healthcare system
in Australia. It proves timely in relation to the Government’s proposal to introduce higher and potentially
more consumer copayments, including an emergency
department copayment across the health system.40 The
results of this study may be pivotal in informing policy
development that will support sustainable pharmaceutical budgets, as well as potentially minimising harm to
consumers that may arise from reducing or ceasing medications due to cost.
A recent paper demonstrated that patients without a
concessional card were 63% more likely to discontinue
statin therapy and 60% more likely to fail to adhere to
statin therapy compared with those with a concessional
card over a 1-year period when controlling for factors such
as income, education and a range of clinical factors.24 A
study by Warren, et al27 looked at adherence in long-term
use of statin medication and showed that adherence levels
to statin therapy were high for concessional beneficiaries (80.1%) and lower in general beneficiaries (56.7%).
Both studies demonstrated a higher adherence to statin
medication for concessional beneficiaries, highlighting
the importance to explore these two groups at the time
of medication copayment increase and the effect it had
on adherence, health outcomes and health service utilisation. Literature worldwide has demonstrated that statin
medication use and adherence is price sensitive.5–7 23
However, there is a gap in understanding whether this
places patients at risk of adverse outcome or shifts costs to
other health services such hospitalisation.
Identifying whether there are differences between
consumers who continue their medication, those who
reduce their medication and those who cease their medication will be important in informing policy. The findings
will have implications on future decision making of
increasing a copayment and the consequences for vulnerable populations and long-term outcomes, including
6

people with low income or living in rural and remote
areas.
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